Estradiol benzoate /
testosterone propionate
Estradiol benzoate (top) and
testosterone propionate (bottom)
Combination of
Estradiol benzoateEstrogen
Testosterone propionateAndrogen; Anabolic steroid
Clinical data
Trade namesBothermon
Other namesEB/TP
Routes of
administration		Intramuscular injection
Identifiers
CAS Number

Estradiol benzoate/testosterone propionate (EB/TP), sold under the brand name Bothermon, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone propionate (TP), an androgen/anabolic steroid.[1][2][3][4][5] It contains 0.24 mg/mL EB and 4.76 mg/mL TP in oil solution in each ampoule and is administered by intramuscular injection.[1] The medication was marketed in Japan by 1953[4] and remains available in this country today.[5]

Androgen replacement therapy formulations and dosages used in women
RouteMedicationMajor brand namesFormDosage
OralTestosterone undecanoateAndriol, JatenzoCapsule40–80 mg 1x/1–2 days
MethyltestosteroneMetandren, EstratestTablet0.5–10 mg/day
FluoxymesteroneHalotestinTablet1–2.5 mg 1x/1–2 days
NormethandroneaGinecosideTablet5 mg/day
TiboloneLivialTablet1.25–2.5 mg/day
Prasterone (DHEA)b–Tablet10–100 mg/day
SublingualMethyltestosteroneMetandrenTablet0.25 mg/day
TransdermalTestosteroneIntrinsaPatch150–300 μg/day
AndroGelGel, cream1–10 mg/day
VaginalPrasterone (DHEA)IntrarosaInsert6.5 mg/day
InjectionTestosterone propionateaTestovironOil solution25 mg 1x/1–2 weeks
Testosterone enanthateDelatestryl, Primodian DepotOil solution25–100 mg 1x/4–6 weeks
Testosterone cypionateDepo-Testosterone, Depo-TestadiolOil solution25–100 mg 1x/4–6 weeks
Testosterone isobutyrateaFemandren M, FolivirinAqueous suspension25–50 mg 1x/4–6 weeks
Mixed testosterone estersClimacteronaOil solution150 mg 1x/4–8 weeks
Omnadren, SustanonOil solution50–100 mg 1x/4–6 weeks
Nandrolone decanoateDeca-DurabolinOil solution25–50 mg 1x/6–12 weeks
Prasterone enanthateaGynodian DepotOil solution200 mg 1x/4–6 weeks
ImplantTestosteroneTestopelPellet50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

References

  1. 1 2 伴一郎, & 杉山陽一. (1956). 男性ホルモンと黄体ホルモンとの混合製剤 Testoluton の使用成績. [Testoluton (Schering), A Combined Preparation of Testosterone Propionate and Progesterone Applied for Clinical Use] 産婦人科の進歩, 8(2), 100-103. https://www.jstage.jst.go.jp/article/sanpunosinpo1949/8/2/8_2_100/_pdf
  2. ↑ 村上清. (1959). 産科婦人科的ホルモン療法の概況 (本邦). [Overview of obstetrics and gynecology hormone therapy (in Japan).] 産婦人科の進歩, 11(Special), 6-30. https://www.jstage.jst.go.jp/article/sanpunosinpo1949/11/Special/11_Special_6/_pdf
  3. ↑ 山村博三. (1956). 機能性子宮出血の性ホルモン療法. [Sex hormone therapy for functional uterine bleeding.] 関西医科大学雑誌, 8(4), 293-299. https://www.jstage.jst.go.jp/article/jkmu1956/8/4/8_293/_pdf
  4. 1 2 植田安雄, & 辻井翠. (1953). 月経困難症に対する Androgenestrogen 混合剤 Bothermon の応用 (治療成績). [Application of Androgenestrogen Bothermon for dysmenorrhea (treatment results).] ホルモンと臨床, 1(4), 333-337. https://ci.nii.ac.jp/naid/40018513715/
  5. 1 2 "Archived copy". Archived from the original on 2019-04-07. Retrieved 2019-06-09.{{cite web}}: CS1 maint: archived copy as title (link)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.